KIT2014 is a novel inhaled peptide therapy being developed for respiratory diseases including chronic obstructive pulmonary disease (COPD), ...
PQQ and ergothioneine have drawn growing interest in beauty research, but published human skin data on oral PQQ remain scarce ...
公開資訊觀測站重大訊息公告(7871)安立璽榮-KY-代重要子公司安立璽榮生醫股份有限公司公告，用於治療阿茲海默症之新藥EI-1071，獲台灣衛生福利部食品藥物管理署(TFDA)核准執行食物影響第一期臨床試驗1.事實發生日:115/09/242.研發 ...
Research that won the 10th Bioindustry AwardOn July 15, 2026, Sumitomo Pharma Co., Ltd. and RACTHERA Inc. announced that the ...
WINNIPEG, MB / ACCESS Newswire / September 28, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of ...
제10회 바이오인더스트리 대상 수상 연구2026년 7월 15일, 스미토모 파마 주식회사 및 주식회사 RACTHERA는 교토 대학과의 공동 연구 성과인 비자기 iPS 세포 유래 도파민 신경 전구 세포 ...
Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part A data to provide an interim clinical update by ...
Phase 3 trial data show significant scalp, eyelash, and eyebrow hair regrowth at 36 weeks in adolescents treated with oral baricitinib.
Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.
Amgen’s phase 3 OASIZ 301 trial shows dazodalibep significantly improves systemic disease activity in adults with moderate to severe Sjögren disease at week 48.
14h
Medicure, Inc.: Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
WINNIPEG, MB / ACCESS Newswire / September 28, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceutic ...
The FDA has approved Gazyva (obinutuzumab) to reduce relapse risk in adult and pediatric patients aged 2 years and older with idiopathic nephrotic syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results